Sanofi (SNY) US Services’ rilzabrutinib was granted FDA orphan designation status as a treatment of sickle cell disease, according to a post to the agency’s website.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Sanofi to invest at least $20B in U.S. through 2030
- U.S. biotech companies debate relocating trials outside U.S., Reuters reports
- Trump’s drug-price crackdown may lead to minor concessions, WSJ reports
- JPMorgan sees ‘most favored nation’ drug order facing ‘significant push back’
- White House publishes Trump executive order aimed at lowering drug prices